Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs

Immuneering

06/03/2026 12:56

Overview

Oncology company's Q4 loss per share beat analyst expectations

Net loss for Q4 beat analyst estimates

Company ended 2025 with $217 mln in cash, funding operations into 2029

Result Drivers

LOWER RESEARCH AND DEVELOPMENT (R&D) EXPENSES: R&D expenses for the fourth quarter of 2025 were $9.3 million compared to $14.9 million for the fourth quarter of 2024.

CASH POSITION - Ended 2025 with $217 mln in cash, ensuring funding into 2029

Company press release: ID:nGNX2KvBt6

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
Beat
-$0.18
-$0.31 (6 Analysts)
Q4 Net Income
Beat
-$11.60 mln
-$20.81 mln (4 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Immuneering Corp is $14.00, about 181.1% above its March 5 closing price of $4.98

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)